Clinical Trial Update: A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study of CT1195E in relapsed/refractory B-cell neoplasms is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CT1195E

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL | Phase 1 | Status: NOT_YET_RECRUITING